Oxaliplatin combined with 5-FU in second line treatment of advanced pancreatic adenocarcinoma. Results of a phase II trial.

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Gastroentérologie Clinique et Biologique

• Publication date

  2006-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S0399-8320(06)73188-8PMID 16633299
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial.

  2005cited by this paper
• Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate.

  2004cited by this paper
• Randomized phase II study evaluating oxaliplatin alone, oxaliplatin combined with infusional 5-FU, and infusional 5-FU alone in advanced pancreatic carcinoma patients.

  2004cited by this paper
• Irinotecan plus raltitrexed vs raltitrexed alone in patients with gemcitabine-pretreated advanced pancreatic adenocarcinoma

  2003cited by this paper
• Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma.

  2003cited by this paper
• Gemcitabine and oxaliplatin for metastatic pancreatic adenocarcinoma: a North Central Cancer Treatment Group phase II study.

  2003cited by this paper
• Gemcitabine combined with oxaliplatin in advanced pancreatic adenocarcinoma: final results of a GERCOR multicenter phase II study.

  2002cited by this paper
• Phase II trial of 5-fluorouracil plus eniluracil in patients with advanced pancreatic cancer: a Southwest Oncology Group study.

  2002cited by this paper
• A Phase II study of gemcitabine and docetaxel in patients with metastatic pancreatic carcinoma

  2002cited by this paper
• Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma

  2002cited by this paper
• Weekly gemcitabine plus Epirubicin as effective chemotherapy for advanced pancreatic cancer: a multicenter phase II study

  2002cited by this paper
• Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297.

  2002cited by this paper
• Irinotecan combined with gemcitabine, 5-fluorouracil, leucovorin, and cisplatin (G-FLIP) is an effective and noncrossresistant treatment for chemotherapy refractory metastatic pancreatic cancer.

  2001cited by this paper
• Use of the ratio of time to progression following first- and second-line therapy to document the activity of the combination of oxaliplatin with 5-fluorouracil in the treatment of colorectal carcinoma.

  2001cited by this paper
• A phase II trial of biweekly high dose gemcitabine for patients with metastatic pancreatic adenocarcinoma

  2000cited by this paper
• Gemcitabine and cisplatin in the treatment of advanced or metastatic pancreatic cancer.

  2000cited by this paper
• Paclitaxel as weekly second-line therapy in patients with advanced pancreatic carcinoma

  2000cited by this paper
• Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.

  2000cited by this paper
• There are no bad anticancer agents, only bad clinical trial designs--twenty-first Richard and Hinda Rosenthal Foundation Award Lecture.

  1998cited by this paper
• There are no bad anticancer agents, only bad clinical trial designs--twenty-first Richard and Hinda Rosenthal Foundation Award Lecture.

  1998cited by this paper
• Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.

  1997cited by this paper
• Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer.

  1996cited by this paper
• The national cancer data base report on pancreatic cancer

  1995cited by this paper
• Chemotherapy prolongs survival in inoperable pancreatic carcinoma

  1994cited by this paper
• Reporting results of cancer treatment

  1981cited by this paper

• Chemotherapy and radiotherapy for advanced pancreatic cancer.

  2024cites this paper
• Chemotherapy and radiotherapy for advanced pancreatic cancer.

  2018cites this paper
• Capecitabine and oxaliplatin as first and second line treatment for locally advanced and metastatic pancreatic ductal adenocarcinoma.

  2017cites this paper
• Second-line chemotherapy for advanced pancreatic cancer: Which is the best option?

  2017cites this paper
• Second-line treatment in inoperable pancreatic adenocarcinoma: A systematic review and synthesis of all clinical trials.

  2015cites this paper
• Second-line capecitabine and oxaliplatin combination for gemcitabine-resistant advanced pancreatic cancer.

  2014cites this paper
• FOLFOX as second-line chemotherapy in patients with pretreated metastatic pancreatic cancer from the FIRGEM study

  2014cites this paper
• Beyond first-line chemotherapy for advanced pancreatic cancer: an expanding array of therapeutic options?

  2014cites this paper
• Folfox4 as a rescue chemotherapy for gemcitabine-refractory pancreatic cancer.

  2013cites this paper
• Histamine regulation of pancreatitis and pancreatic cancer: a review of recent findings.

  2013cites this paper
• Cisplatin-Modified De Gramont in Second-Line Therapy for Pancreatic Adenocarcinoma

  2013cites this paper
• Second-line treatment in advanced pancreatic cancer: a comprehensive analysis of published clinical trials.

  2013cites this paper
• Conventional chemotherapy of advanced pancreatic cancer.

  2012cites this paper
• A review of clinical trials of chemotherapy for pancreatic cancer

  2012cites this paper
• A prognostic model to identify patients with advanced pancreas adenocarcinoma who could benefit from second-line chemotherapy.

  2012cites this paper
• Second-line chemotherapy with Capecitabine (Xeloda) and Docetaxel (Taxotere) in previously treated, unresectable adenocarcinoma of pancreas: the final results of a phase II trial

  2011cites this paper
• Phase I study of the botanical formulation PHY906 with capecitabine in advanced pancreatic and other gastrointestinal malignancies.

  2010cites this paper
• Combination 5-fluorouracil, folinic acid and cisplatin (LV5FU2-CDDP) followed by gemcitabine or the reverse sequence in metastatic pancreatic cancer: final results of a randomised strategic phase III trial (FFCD 0301)

  2010cites this paper
• Cucurbitacin B, a novel in vivo potentiator of gemcitabine with low toxicity in the treatment of pancreatic cancer

  2010cites this paper
• Systemic therapy for metastatic pancreatic adenocarcinoma

  2010cites this paper
• Clinical Decision Making in Pancreatic Cancer

  2010cites this paper
• RESEARCH PAPER Cucurbitacin B, a novel in vivo potentiator of gemcitabine with low toxicity in the treatment of pancreatic cancer

  2010cites this paper
• Second-and third-line chemotherapy in patients with metastatic pancreatic adenocarcinoma : Feasibility and potential benefits in a retrospective series of 117 patients Deuxième et troisième lignes de chimiothérapie chez des patients ayant un adénocarcinome du pancréas métastatique : faisabilité et b

  2009cites this paper
• Cucurbitacin B induces apoptosis by inhibition of the JAK/STAT pathway and potentiates antiproliferative effects of gemcitabine on pancreatic cancer cells.

  2009cites this paper
• Second-line therapy for advanced pancreatic cancer: a review of the literature and future directions.

  2009cites this paper
• Oxaliplatin, 5-Fluorouracil, and Leucovorin as Second-Line Treatment for Advanced Pancreatic Cancer

  2009cites this paper
• Second- and third-line chemotherapy in patients with metastatic pancreatic adenocarcinoma: feasibility and potential benefits in a retrospective series of 117 patients.

  2009cites this paper
• An open label randomized multicentre phase IIIb trial comparing parenteral substitution versus best supportive nutritional care in subjects with pancreatic adenocarcinoma receiving 5-FU plus oxaliplatin as 2nd or higher line chemotherapy regarding clinical benefit - PANUSCO

  2009cites this paper
• Phase II study of 5-fluorouracil and paclitaxel in patients with gemcitabine-refractory pancreatic cancer

  2009cites this paper
• Comment prendre en charge en pratique un adénocarcinome pancréatique en chimiothérapie

  2008cites this paper
• Short Time to Progression under First-Line Chemotherapy Is a Negative Prognostic Factor for Time to Progression and Residual Survival under Second-Line Chemotherapy in Advanced Pancreatic Cancer

  2008cites this paper
• Gemcitabine in the treatment of metastatic pancreatic cancer

  2008cites this paper
• A phase II study of S-1 in gemcitabine-refractory metastatic pancreatic cancer

  2008cites this paper
• Optimal second line treatment options for gemcitabine refractory advanced pancreatic cancer patients. Can we establish standard of care with available data?

  2008cites this paper
• The role of second-line chemotherapy after gemcitabine failure in patients with advanced pancreatic cancer.

  2008cites this paper
• S3-Guideline “Exocrine Pancreatic Carcinoma” 20071

  2008cites this paper
• Phase 2 trial of oxaliplatin plus capecitabine (XELOX) as second‐line therapy for patients with advanced pancreatic cancer

  2008cites this paper
• S3-Leitlinie „Exokrines Pankreaskarzinom” 2007

  2007cites this paper
• Treatment of advanced pancreatic cancer.

  2007cites this paper
• Cancer digestif Gastrointestinal cancer

  2007cites this paper
• The management of pancreatic cancer. Current expert opinion and recommendations derived from the 8th World Congress on Gastrointestinal Cancer, Barcelona, 2006.

  2007cites this paper
• Chemotherapy for Pancreatic Cancer: From Metastatic Disease to Adjuvant Therapy

  2007cites this paper
• [S3-Guidelines "Exocrine pancreatic cancer" 2007].

  2007cites this paper
• Second-line chemotherapy in advanced pancreatic carcinoma: a multicenter survey of the Gruppo Oncologico Italia Meridionale on the activity and safety of the FOLFOX4 regimen in clinical practice.

  2007cites this paper
• A phase II study of S-1 in gemcitabine-refractory metastatic pancreatic cancer.

  2006cites this paper